Biomarker Research in Musculoskeletal Disease

描述(由申请人提供)： 道格拉斯·C·鲍尔，医学博士，加州大学旧金山分校医学、流行病学和生物统计学副教授，作为一名研究人员、教育家和临床医生，有着良好的记录。在1992年完成临床流行病学研究员培训后，Bauer博士与Steven Cummings博士一起接受了为期3年的职业发展指导奖。他目前是普通内科研究部主任，也是加州大学旧金山分校协调中心(UCSF CC)的核心教员。 候选人建议建立一个以患者为导向的研究计划，重点是在肌肉骨骼和衰老研究中使用生物标记物。该计划的目标是在加州大学旧金山分校的住院医师、研究员和初级教员中促进以患者为中心的研究，并为初级研究人员提供机会，以更好地了解生物标记物的方法学并在他们的研究中使用生物标记物。 利用加州大学旧金山分校现有的许多临床研究培训资源和鲍尔博士通过加州大学旧金山分校CC提供的几个大型骨质疏松临床试验数据库，该项目的总体目标是：1)指导住院医师、临床研究员和初级教员进行以患者为中心的研究；2)为希望在以患者为导向的肌肉骨骼研究中使用生物标记物的学员提供专业知识和机会；3)增进我们对骨质疏松生物标记物的理解。鲍尔博士研究计划的具体目的是：1)确定由选定的生物标记物的基线水平确定的几种抗吸收治疗骨质疏松症的抗骨折疗效的差异，这些生物标记物包括雌二醇和骨转换标志物；2)比较在阿伦磷酸钠、雷洛昔芬和雌激素-孕激素的临床试验中，骨转换的生化标志物变化作为骨折结果替代品的充分性；以及3)比较几种骨质疏松症治疗方法，包括阿仑膦酸盐、雷洛昔芬和雌激素-孕激素，通过骨密度的变化以及骨转换的生化标志物的变化来调节抗骨折效果的程度。 K24的资金将使鲍尔博士能够减少他的临床和管理责任，并将他的努力集中在促进和教授以患者为导向的研究上。

DESCRIPTION (provided by applicant): Douglas C. Bauer, MD is an Associate Professor of Medicine, and Epidemiology and Biostatistics at the University of California, San Francisco, with an established track record as a researcher, educator, and clinician. After completing fellowship training in clinical epidemiology in 1992, Dr Bauer undertook a 3 year mentored career development award with Dr. Steven Cummings. He is currently Director of Research for the Division of General Internal Medicine, and is a core faculty member of the UCSF Coordinating Center (UCSF CC). The candidate proposes building a program of patient-oriented research focused on the use of biomarkers in musculoskeletal and aging research. The objectives of the program are to promote patient-oriented research at UCSF among medical residents, fellows, and junior faculty, and to provide junior investigators with opportunities to better understand biomarker methodology and utilize biomarkers in their research. Using the many clinical research training resources available at UCSF and several large osteoporosis clinical trial databases available to Dr. Bauer through the UCSF CC, the overall aims of this program are: 1) to mentor medical residents, clinical research fellows, and junior faculty to conduct patient-oriented research; 2) to provide expertise and opportunities for mentees who wish to utilize biomarkers in patient-oriented musculoskeletal research and 3) to advance our understanding of biomarkers in osteoporosis. The specific aims of Dr. Bauer's research plan are: 1) To determine differences in the anti-fracture efficacy of several anti-resorptive treatments for osteoporosis defined by baseline levels of selected biomarkers, including estradiol and markers of bone turnover; 2) To compare the adequacy of change in biochemical markers of bone turnover to serve as a surrogate for fracture outcomes in clinical trials of alendronate, raloxifene, and estrogen-progestin; and 3) To compare the degree of mediation of the anti-fracture effect of several osteoporosis treatments, including alendronate, raloxifene, and estrogen-progestins, by change in BMD as well as change in biochemical markers of bone turnover. Funding of this K24 will allow Dr. Bauer to reduce his clinical and administrative responsibilities, and focus his efforts on promoting and teaching patient-oriented research.